EA033007B1 - ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ - Google Patents

ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ

Info

Publication number
EA033007B1
EA033007B1 EA201590162A EA201590162A EA033007B1 EA 033007 B1 EA033007 B1 EA 033007B1 EA 201590162 A EA201590162 A EA 201590162A EA 201590162 A EA201590162 A EA 201590162A EA 033007 B1 EA033007 B1 EA 033007B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
ospa
lipidated
heterodimer
producing
Prior art date
Application number
EA201590162A
Other languages
English (en)
Russian (ru)
Other versions
EA201590162A1 (ru
Inventor
Пер Комстедт
Урбан Лундберг
Андреас Майнке
Маркус Ханнер
Вольфганг Шюлер
Бенджамин Вайзел
Кристоф Райниш
Брижитт Громанн
Роберт Шлегль
Original Assignee
Валнева Аустриа Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Валнева Аустриа Гмбх filed Critical Валнева Аустриа Гмбх
Publication of EA201590162A1 publication Critical patent/EA201590162A1/ru
Publication of EA033007B1 publication Critical patent/EA033007B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201590162A 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ EA033007B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (2)

Publication Number Publication Date
EA201590162A1 EA201590162A1 (ru) 2015-06-30
EA033007B1 true EA033007B1 (ru) 2019-08-30

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590162A EA033007B1 (ru) 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
EA201991059A EA201991059A1 (ru) 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201991059A EA201991059A1 (ru) 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Country Status (24)

Country Link
US (9) US8986704B2 (https=)
EP (3) EP3360568B1 (https=)
JP (1) JP6276258B2 (https=)
KR (2) KR102190981B1 (https=)
CN (2) CN107602676B (https=)
AU (2) AU2013285364B2 (https=)
CA (1) CA2876541C (https=)
CY (1) CY1120772T1 (https=)
DK (1) DK2869839T3 (https=)
EA (2) EA033007B1 (https=)
ES (2) ES2688883T3 (https=)
HR (1) HRP20181689T1 (https=)
HU (1) HUE041286T2 (https=)
LT (1) LT2869839T (https=)
MX (2) MX391136B (https=)
NZ (2) NZ703597A (https=)
PL (1) PL2869839T3 (https=)
PT (1) PT2869839T (https=)
RS (1) RS57847B1 (https=)
SI (1) SI2869839T1 (https=)
SM (1) SMT201800557T1 (https=)
TR (1) TR201815419T4 (https=)
WO (1) WO2014006226A1 (https=)
ZA (1) ZA201409222B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HUE043779T2 (hu) * 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
RU2689315C2 (ru) * 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
US11197826B2 (en) * 2015-12-23 2021-12-14 Novartis Ag Oil-in-water emulsions including retinoic acid
WO2017139715A1 (en) * 2016-02-11 2017-08-17 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
CA3174599A1 (en) * 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
CA3230594A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
PL2068918T5 (pl) * 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
WO2011031568A2 (en) 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
JP6304888B2 (ja) 2011-12-06 2018-04-04 ムベア カルボ テック ゲーエムベーハーＭｕｂｅａ Ｃａｒｂｏ Ｔｅｃｈ Ｇｍｂｈ 繊維強化材料製ホイールおよび対応するホイールの作製方法
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HUE043779T2 (hu) 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CN108884134A (zh) 2015-12-10 2018-11-23 加拿大全国研究委员会 脂化肺炎链球菌抗原组合物、制备方法和用途
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEBORAH FASS: "Disulfide Bonding in Protein Biophysics", ANNUAL REVIEW OF BIOPHYSICS, ANNUAL REVIEWS, vol. 41, no. 1, 9 June 2012 (2012-06-09), pages 63 - 79, XP055080113, ISSN: 1936122X, DOI: 10.1146/annurev-biophys-050511-102321 *
DING, W. HUANG, X. YANG, X. DUNN, J.J. LUFT, B.J. KOIDE, S. LAWSON, C.L.: "Structural identification of a key protective B-cell epitope in lyme disease antigen OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 302, no. 5, 6 October 2000 (2000-10-06), United Kingdom, pages 1153 - 1164, XP004472344, ISSN: 0022-2836, DOI: 10.1006/jmbi.2000.4119 *
HERTADI, R. ; GRUSWITZ, F. ; SILVER, L. ; KOIDE, A. ; KOIDE, S. ; ARAKAWA, H. ; IKAI, A.: "Unfolding Mechanics of Multiple OspA Substructures Investigated with Single Molecule Force Spectroscopy", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 333, no. 5, 7 November 2003 (2003-11-07), United Kingdom, pages 993 - 1002, XP027101255, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2003.09.010 *
KOIDE, S. YANG, X. HUANG, X. DUNN, J.J. LUFT, B.J.: "Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 350, no. 2, 8 July 2005 (2005-07-08), United Kingdom, pages 290 - 299, XP004927295, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2005.04.066 *
LI H ET AL: "Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab.", NATIONAL ACADEMY OF SCIENCES, US, vol. 94, no. 8, 15 April 1997 (1997-04-15), US, pages 3584 - 3589, XP002456095, ISSN: 0027-8424, DOI: 10.1073/pnas.94.8.3584 *
VAN HOECKE, C. COMBERBACH, M. DE GRAVE, D. DESMONS, P. FU, D. HAUSER, P. LEBACQ, E. LOBET, Y. VOET, P.: "Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 17, 1 December 1996 (1996-12-01), AMSTERDAM, NL, pages 1620 - 1626, XP004016822, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(96)00146-6 *

Also Published As

Publication number Publication date
US20170107263A1 (en) 2017-04-20
SMT201800557T1 (it) 2018-11-09
HRP20181689T1 (hr) 2018-12-28
CN104487084B (zh) 2017-09-22
EP2869839B1 (en) 2018-09-05
US10544194B2 (en) 2020-01-28
US20230295245A1 (en) 2023-09-21
CY1120772T1 (el) 2019-12-11
US12195501B2 (en) 2025-01-14
KR102190981B1 (ko) 2020-12-15
KR102393038B1 (ko) 2022-04-29
WO2014006226A1 (en) 2014-01-09
PL2869839T3 (pl) 2018-12-31
EP3360568B1 (en) 2020-03-04
TR201815419T4 (tr) 2018-11-21
CN107602676A (zh) 2018-01-19
US20180327460A1 (en) 2018-11-15
JP2015522270A (ja) 2015-08-06
ES2688883T3 (es) 2018-11-07
US20150250865A1 (en) 2015-09-10
US11208439B2 (en) 2021-12-28
MX364623B (es) 2019-05-03
EA201991059A1 (ru) 2020-01-31
US20170101446A1 (en) 2017-04-13
PT2869839T (pt) 2018-11-12
HK1207982A1 (en) 2016-02-19
HK1209370A1 (en) 2016-04-01
KR20150036191A (ko) 2015-04-07
DK2869839T3 (en) 2018-10-15
KR20200141096A (ko) 2020-12-17
MX2015000013A (es) 2015-06-04
EP3360568A1 (en) 2018-08-15
MX391136B (es) 2025-03-21
US20150232517A1 (en) 2015-08-20
CN104487084A (zh) 2015-04-01
AU2017218974C1 (en) 2020-02-20
ZA201409222B (en) 2016-08-31
US8986704B2 (en) 2015-03-24
CA2876541A1 (en) 2014-01-09
EA201590162A1 (ru) 2015-06-30
JP6276258B2 (ja) 2018-02-07
AU2017218974B2 (en) 2019-05-30
CA2876541C (en) 2022-03-01
EP3689372A1 (en) 2020-08-05
EP2869839A1 (en) 2015-05-13
EP3689372B1 (en) 2026-04-29
HK1257893A1 (en) 2019-11-01
SI2869839T1 (sl) 2018-11-30
AU2013285364A1 (en) 2015-01-29
HK1248244A1 (zh) 2018-10-12
US9926343B2 (en) 2018-03-27
NZ733026A (en) 2019-09-27
US11466058B2 (en) 2022-10-11
US20140010835A1 (en) 2014-01-09
NZ703597A (en) 2017-06-30
RS57847B1 (sr) 2018-12-31
AU2013285364B2 (en) 2017-06-15
US20220185851A1 (en) 2022-06-16
ES2800873T3 (es) 2021-01-04
US20200239525A1 (en) 2020-07-30
CN107602676B (zh) 2021-06-04
LT2869839T (lt) 2018-11-12
HUE041286T2 (hu) 2019-05-28
AU2017218974A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
MX2020010399A (es) 3-epimerasa.
IN2015KN00414A (https=)
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
FI3564378T3 (fi) Immunogeeninen koostumus
GB201118201D0 (en) Novel peptides
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
IN2014DN06920A (https=)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
MY193807A (en) T-cell receptor and uses thereof
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
NZ614255A (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
NZ700467A (en) Treatments suitable for malassezia infections
WO2015054439A3 (en) Hybrid factor viii polypeptides for use to treat hemophilia a
WO2015048785A3 (en) Mosaic conserved region hiv immunogenic polypeptides
NZ707753A (en) Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
MY166516A (en) Tomm34 peptides and vaccines including the same